Literature DB >> 10527256

Predictability and significance of multifocal prostate cancer in the radical prostatectomy specimen.

B Djavan1, M Susani, B Bursa, A Basharkhah, R Simak, M Marberger.   

Abstract

Multifocal prostate cancer has been reported in 50-76% of all cases of radical retropubic prostatectomy (RRP) specimens, but the clinical and prognostic significance of this finding is still unclear. A retrospective analysis of patients who underwent RRP between 1993 and 1997 was performed. Preoperative screening parameters and 4-mm RRP specimen sections were examined. The location, Gleason score, and extracapsular extension of the tumor recorded. Three hundred eight cases were reviewed. Mean follow-up was 4.2 +/- 1 years (range 2-6 years). Two hundred six patients (66.9%) had multifocal prostate cancer and 102 (33.1%) had unifocal prostate cancer. Of those with multifocal disease, 63% had two foci and 37% had three or more foci. There were statistical significant differences between both groups with respect to preoperative prostate-specific antigen (PSA) density of the transition zone (PSA-TZ), free/total (f/t) PSA, as well as percentage of patients with organ confined disease, high-grade tumors, and local recurrence. PSA-TZ (p = .001) and f/t PSA (p = .004) were significantly different between patients with unifocal and multifocal disease (0.9 vs. 2.2 ng/mL/cc and 18% vs. 6.5%, respectively). However, preoperative PSA (11.2 vs. 12.8 ng/mL; p = .09) and PSA density (0.17 vs. 0.19 ng/mL/cc; p = .07) were not able to predict unifocality or multifocality. These data suggest that multifocal prostate cancer is associated with higher grade, stage, and recurrence rate than unifocal prostate cancer. Preoperative PSA-TZ (> 1.5 ng/mL/cc) and f/t PSA (<9%) may predict multifocality in the RRP specimen.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10527256

Source DB:  PubMed          Journal:  Tech Urol        ISSN: 1079-3259


  26 in total

1.  Focal therapy: a new paradigm for the treatment of prostate cancer.

Authors:  Basir Tareen; Guilherme Godoy; Samir S Taneja
Journal:  Rev Urol       Date:  2009

Review 2.  Novel techniques for the treatment of localized prostate cancer: evidence of efficacy?

Authors:  Marnie R Robinson; Judd W Moul
Journal:  Curr Urol Rep       Date:  2007-05       Impact factor: 3.092

Review 3.  Biopsy standards for detection of prostate cancer.

Authors:  Bob Djavan; Markus Margreiter
Journal:  World J Urol       Date:  2007-03-07       Impact factor: 4.226

Review 4.  Translational and clinical implications of the genetic landscape of prostate cancer.

Authors:  Daniel E Spratt; Zachary S Zumsteg; Felix Y Feng; Scott A Tomlins
Journal:  Nat Rev Clin Oncol       Date:  2016-06-01       Impact factor: 66.675

5.  Targeted focal therapy for prostate cancer: a review of the literature.

Authors:  Kathryn F Sullivan; E David Crawford
Journal:  Ther Adv Urol       Date:  2009-08

6.  Optimal prostate biopsy regimen.

Authors:  Ryan K Berglund; J Stephen Jones
Journal:  Curr Urol Rep       Date:  2012-12       Impact factor: 3.092

Review 7.  Pathologic basis of focal therapy for early-stage prostate cancer.

Authors:  Vladimir Mouraviev; Janice M Mayes; Thomas J Polascik
Journal:  Nat Rev Urol       Date:  2009-04       Impact factor: 14.432

Review 8.  Active surveillance and radical therapy in prostate cancer: can focal therapy offer the middle way?

Authors:  Hashim Uddin Ahmed; Mark Emberton
Journal:  World J Urol       Date:  2008-08-14       Impact factor: 4.226

Review 9.  An update on focal therapy for prostate cancer.

Authors:  Marlon Perera; Nishanth Krishnananthan; Uri Lindner; Nathan Lawrentschuk
Journal:  Nat Rev Urol       Date:  2016-09-27       Impact factor: 14.432

10.  Residual tumor potentially left behind after local ablation therapy in prostate adenocarcinoma.

Authors:  Ghil Suk Yoon; Wenle Wang; Adeboye O Osunkoya; Zhaoli Lane; Alan W Partin; Jonathan I Epstein
Journal:  J Urol       Date:  2008-04-18       Impact factor: 7.450

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.